Alimera Sciences Profile

1.25
USD 0.01  0.79%
84%
75%

Acquisition by Myers C Daniel of 2494 shares of Alimera Sciences subject to Rule 16b-3

Alimera Sciences Inc insider trading alert for grant of common stock by Myers C Daniel, CEO, on February 8, 2018. This event was filed by Alimera Sciences Inc with SEC on 2018-02-08. Annual statement of changes in beneficial ownership - SEC Form 5 [view details]   

Alimera Sciences Summary

Alimera Sciences Inc (ALIM) is traded on NASDAQ General Markets in USA. It is located in GEORGIA, U.S.A and employs 125 people. Alimera Sciences is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Micro-Cap' category with current market capitalization of 88.51 M. Alimera Sciences Inc conducts business under Healthcare sector and is part of Pharmaceutical Products industry. This company has 69.15 M outstanding shares of which 849.84 K shares are presently shorted by private and institutional investors with about 3.56 trading days to cover. Alimera Sciences currently holds about 25.62 M in cash with (13.57 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.37.
Check Alimera Sciences Probability Of Bankruptcy

Ownership Allocation (%)

Top Holders

Selected Alimera Sciences Inc Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

Alimera Sciences Against Markets

Risk Adjusted
Performance Score (0 to 100)
7 
Chance of
Financial Distress (0 to 100%)
< 77% 
Equity ratings for Alimera Sciences Inc are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. Alimera Sciences, Inc. was founded in 2003 and is headquartered in Alpharetta, Georgia. Alimera Sciences operates under Drug Manufacturers - Major classification in USA and traded on NASDAQ General Markets exchange. It employs 125 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
NameAlimera Sciences Inc
President CEO, DirectorDaniel MyersAll Leadership
Analyst Consensus
Piotroski F Score
Macroaxis Advice
InstrumentUSA Stock Stocks Directory
RegionNorth America
LocationGEORGIA, U.S.A
Business Address6120 Windward Parkway
ExchangeNASDAQ General Markets
CIK Number01267602.0
CUSIP016259103
SectorHealthcare
IndustryPharmaceutical Products
BenchmarkDOW
Websitewww.alimerasciences.com
Contact Number678 990 5740
CurrencyUSD - US Dollar

Recommendations

Alimera Sciences Analyst Recommendations
Target PriceAdvice# of Analysts
3.0Strong Buy1Odds
Alimera Sciences Inc current and past analyst recommendations published by number of research institutions as well as average analyst consensus
Alimera Sciences Analyst Advice  

Opportunities

Explore Investment Opportunities
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked.
Explore Investing Ideas  

Earnings

Alimera Sciences Earnings Estimates
EPSEstimate Date
Quarterly Estimate-0.05March 1, 2017
Alimera Sciences Inc normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate  

Directors

Alimera Sciences Corporate Directors
James Largent Independent Director, MBA
Peter Pizzo Independent Director, Ph.D
Brian Halak Independent Director, Ph.D